Oslo, 18. August 2016. Serodus ASA (OAX:SER) announces its results for the second quarter 2016.

Highlights include:

SER150 Diabetic Nephropathy

  • First cohort completed and approved by the Drug Monitoring Safety Board and Ethical Committee with no safety concerns
  • Enrolment for cohort 2 has started and ¼ of patients randomized
  • Continue dialog with potential licensing partners

Financing

  • Completed private placement of 10 MNOK
  • After completing the ongoing Phase 2a study in Diabetic Nephropathy Serodus expect to run a second placement in H1-2017
  • Available financing has historically been significant below ambitions, as a consequence Serodus will evaluate current financing model and will initiate a discussion with large shareholders

Quarterly report and webcast is available on http://www.serodus.com/Investor/Reports/Quarterly-reports

For more information contact:

Tore Kvam

CFO, Serodus ASA

Mobile: +47 959 34 199

e-mail: tore.kvam@serodus.com

Serodus ASA is a Norwegian drug development company, focusing on new therapeutic products for the treatment of metabolic and cardiovascular diseases with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information see www.serodus.com.

Serodus ASA published this content on 18 August 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 20 August 2016 04:25:07 UTC.

Original documenthttp://www.serodus.com/News/2016/Q2-2016-Interim-Results

Public permalinkhttp://www.publicnow.com/view/5D8ADFF9EE6755873076C443AB0F30DDB1BB3D45